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Objectives: According to the GOLD-2011 report pharmacotherapy in stable COPD 
is used to reduce the symptoms, frequency and severity of exacerbations, improve 
health status and exercise tolerance. MethOds: Our aim was to assess the list of 
medicines, which are available in Ukraine for COPD treatment. We compared the 
medications included in the State Formulary of Ukraine with the dosage forms and 
typical doses of COPD medications list provided by GOLD-2011. Also we calculated 
annual course costs for each drug in different dosage forms. The annual course was 
considered as amount of medicine for 365 days in appropriate for COPD basis dosing. 
Information about the medicine prices was obtained from the ukrainian electronic 
pricing database “MORION”. The EUR/UAH exchange rate was 1 EUR = 10.53 UAH 
(20.06.2013) Results: The State Formulary of Ukraine (SFU) contains 19 medicines 
for INN provided by GOLD-2011: 5 INN are in metered dose inhalers (MDI), 5 - in 
dry powder inhalers (DPI), 1 - in smart mist inhaler (SMI), 5 solutions for nebulizer 
and 3 - in tablets. Salbutamol, salmeterol, indacaterol, fluticasone, beclomethasone 
in DPI are not included in the list of SFU, formoterol in MDI and aminophylline, 
prednisone in tablets are not included in this list as well. The most expensive drug 
is tiotropium with annual costs 604.46 EUR for SMI and 533.81 EUR for DPI. The 
annual costs of salmeterol in MDI and formoterol in DPI are 318.55 and 277.30, 
respectively. The cheapest medicine is salbutamol in MDI with 22.13 EUR annually 
but annual costs of salbutamol solution for nebulizer amount 464.48 EUR per year 
per patient. cOnclusiOns: The State Formulary of Ukraine should be reached by 
medicines for COPD management recommended by GOLD. Annual COPD basis costs 
are depending not only from kind of medicine but from it dosage forms as well.
PRS31
ComPaRing CoStS and ConSequenCeS of tReating ChRoniC 
obStRuCtive PulmonaRy diSeaSe with budeSonide/foRmoteRol and 
flutiCaSone/SalmeteRol
Roggeri A.1, Pantaleoni M.2, Pasina C.2, Inzillo V.2, Roggeri D.P.1
1ProCure Solutions sas, Nembro (Bergamo), Italy, 2AstraZeneca Italia, Basiglio (MI), Italy
Objectives: Inhaled corticosteroids in fixed combination with long-acting B2-
agonists could prevent and reduce chronic obstructive pulmonary disease (COPD) 
exacerbations. The aim of this analysis is to compare clinical consequences and direct 
health care costs related to treatment with budesonide/formoterol and fluticasone/
salmeterol for COPD considering the Italian National Health Service (INHS) perspec-
tive. MethOds: Effectiveness data by the PATHOS study, a population-based, retro-
spective, observational registry study conducted in Sweden, in terms of reduction in 
COPD hospitalizations and COPD-related emergency departments (ED) visits were 
considered in order to estimate the differences in resource consumption between 
patients treated with budesonide/formoterol versus fluticasone/salmeterol. Base case 
considers the dosages of the 2 drugs from the PATHOS study, the cost of drugs in 
charge to INHS, COPD hospitalizations costs from Italian real world data and Italian 
national tariffs for COPD-related ED visits. Results: The real world study PATHOS 
demonstrated a significant reduction in COPD hospitalizations and COPD-related ED 
visits with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -21%, 
respectively); average dosages reported were 568 mcg/day for budesonide/formoterol 
(as budesonide dosage) and 783 mcg/day for fluticasone/salmeterol (as fluticasone 
dosage). In the base case, the treatment for 1 year of 100 patients with budesonide/
formoterol lead to a saving of 43.892€ (21.859€ for drugs, 21.864€ for COPD hospitaliza-
tions and 169€ for COPD-related ED visits) corresponding to -25.2% compared with 
fluticasone/salmeterol treatment. In the most conservative sensitivity analysis which 
consider the DDD dosages for the 2 drugs and COPD hospitalizations and COPD-
related ED visits costs from national tariffs, the treatment for 1 year of 100 patients 
with budesonide/formoterol lead to a saving of 15.523€ (5.754€ for drugs, 9.600€ for 
COPD hospitalizations and 169€ for COPD-related ED visits) corresponding to -12.5% 
compared with fluticasone/salmeterol treatment. cOnclusiOns: Treatment with 
budesonide/formoterol compared to fluticasone/salmeterol could lead to a reduction 
in direct health care costs with relevant improvement in clinical outcomes.
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Objectives: To re-evaluate the economic consequences of parenteral glutamine 
supplementation (PGS) in light of the recent metaanalysis confirming that PGS at a 
dose > 0,20 g/kg body weight per day in intensive care unit (ICU) patients is associ-
ated with reduced mortality, infection rate (IR) and length of stay (LOS). MethOds: 
A simulation model was updated with the new meta-analysis data and clinical 
inputs for the control group from Italian ICU population reported in “Progetto 
Margherita”. Costs are evaluated from the perspective of the Italian hospital and 
derive from official sources. Sensitivity analyses are undertaken to test results’ 
reliability Results: PGS is predicted to reduce mortality rates (-29.0%), IR (-21.2%) 
and overall LOS (-1.07 days/patient), yielding a saving of € 1,047 per patient treated. 
Treatment costs are completely offset by the reduction in hospital stay costs and 
antibiotic costs. Probabilistic sensitivity analysis indicates PGS strategy as dominant 
in more than 90% of cases. cOnclusiOns: Also with contemporary comparative 
efficacy data is PGS in ICU patients expected to be effective in improving outcomes 
and containing costs in Italian hospitals providing intensive care.
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Objectives: To estimate the cost-effectiveness of a novel LAMA, glycopyrronium 
(Seebri® Breezhaler), compared with tiotropium (Spiriva®) in COPD patients from a 
Swedish societal perspective. MethOds: A probabilistic Markov model was utilized to 
Heckman two-step selection model was used. The EQ-5D index score was categorized 
into categories with 0.1 gradations. Marginal effects (ME) were estimated to quantify 
the marginal changes in costs corresponding to, for instance, 0.1 increments in the 
EQ-5D index score, or the presence of asthma or asthma treatment. All costs were 
adjusted to 2003 dollars. Results: The EQ-5D index score was a significant predic-
tor of health care costs in all models, as were asthma, asthma treatment and other 
covariates (p< 0.01). The Heckman model suggested a significant positive spending 
bias (p< 0.01). For the 3 groups considered--non-asthma, asthma and asthma with 
treatment--the mean EQ-5D index scores were 0.848, 0.755 and 0.706, respectively. 
The actual mean costs were $2,355, $4,284 and $5,577, respectively. The predicted 
mean costs using Heckman model were $2,673, $4,431 and $5,618, respectively. On 
average, a 0.1 unit improvement in EQ-5D score was associated with $502 cost reduc-
tion in asthma and $693 cost reduction if asthma patients had treatment (p< 0.01). 
However, after adjusting for positive spending bias, the cost reduction was $891 and 
$961 (p< 0.01) for these two groups respectively. Greater cost reductions were associ-
ated with improving EQ-5D scores at the lower end (< 0 to 0.3) and the mid-range (0.5 
to 0.7). cOnclusiOns: HRQoL is an important component of health care resource 
utilization. The findings suggest a significant relationship exists between health care 
costs and HRQoL data. The EQ-5D significantly predicts costs in asthma and asthma 
treatment, especially after adjusting non-random positive health care spending.
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Objectives: Chronic-Obstructive-Pulmonary-Disease (COPD) is a prevalent health 
condition mainly associated with smoking habit, which is considered the reason 
for higher health care resources utilization and related costs in the National health 
System. The aim of this study was to analyze and compare health care resource utili-
zation and costs according to smoking status in patients with COPD in clinical practice 
in Spain. MethOds: A retrospective cohort nested case-control study was designed. 
Cases were current smokers, while two controls (former smokers) per case matched 
for age, sex, duration of COPD, and burden of comorbidity (number of diagnosis and 
Charlson index) were included using data from medical records. Non-institutionalized 
COPD, both genders, 40 years of age and older, seen consecutively over a period of 4 
years before the index date and fulfilling eligibility criteria were considered eligible for 
analysis. Analysis used regression and general linear models with covariates to com-
pare direct and indirect costs and resource utilization. Results: A total of 930 COPD 
medical records were analyzed: 310 corresponding to cases (current smokers) and 630 
to controls (former smokers). Mean age was 69.4 years (84.6% male). COPD was more 
severe in cases; Odds ratio (OR)= 1.7 (95% CI 1.1;2.1), and higher percentage of current 
smokers had exacerbations [OR= 2,7 (2.0;3.8)], with 4.2 vs. 1.7 exacerbations per year, 
respectively, on average (p< 0.001). Smokers used more physicians visits both at pri-
mary care and specialized level, and emergency room as well. Drugs-based therapies 
were more common in current smokers COPD subjects. As a consequence, smokers 
had higher average annual health care costs; € 3,784 (1,888) vs. € 2,302 (2,451) in former 
smokers (p< 0.001). cOnclusiOns: COPD smoker patients had more exacerbations 
and higher severity of disease. Also, used more health care resources, particularly 
physicians visits and drugs-based therapies resulting in higher health care costs to 
the national health System.
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Objectives: In Finland a new Tobacco Act entered into force in October 2010 with 
the aim of limiting marketing and supply of tobacco products. The long-term objec-
tive of the Finnish government is to make Finland tobacco-free by 2040. Several 
work places and organizations have declared themselves non-smoking. The city 
of Mikkeli with a population of 55 000, has declared itself a non-smoking city and 
has established a non-smoking clinic in September 2011. Citizens contacting public 
health care and willing to quit smoking will be referred to the clinic. MethOds: 
Cross-sectional data was gathered 12 months after the establishment of the clinic. 
Costs related to investment and clinic’s resource utilization were estimated. A health 
care perspective was applied. Results: We studied 74 citizens, who had a least one 
visit during the first year since the establishment of the clinic. Of them 37% man-
aged to quit smoking. Investment costs related to planning and training of nurses 
were 168€ per quitter. Operational costs were 141-167€ per quitter. Total costs per 
quitter were 309-335€ . In the future investment costs per customer will decrease 
as investment costs were nonrecurring. cOnclusiOns: Our results were slightly 
better than what was achieved in an occupational health care non-smoking project 
in Finland (37% vs. 31%). In 2010 the average total costs of occupational health care 
were 340€ per employee in Finland. This is almost the same as the costs per quitter 
in this study. Cost of cigarettes is about 1800€ per average smoker in Finland. Health 
care costs related to lung cancer and stroke are about 18500€ per case during the 
first year. Pharmacological treatment costs about 200-400€ to quitter in average. 
Investing in smoking clinic is justified from economic and effectiveness point of 
views. The non-smoking clinic is still in operation.
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(absorbent). Three additional sub-states: without exacerbation, mild and severe 
exacerbation were considered. The effectiveness of treatment options and utilities 
for each health state were taken from the literature. Only direct health care costs 
were considered. Disease management and exacerbation costs were obtained from 
the literature. Drug costs were calculated based on ex-factory prices with mandatory 
7.5% rebate. All costs were updated to € 2012. A 3% annual discount rate on costs and 
health outcomes was applied. Incremental ratios in terms of cost per life-year gained 
(LYG) and cost per quality-adjusted life-year gained (QALY) of the most effective 
therapy versus the comparator were calculated. One-way sensitivity analyses were 
performed modifying the following parameters: time horizon (10 years, lifetime), 
discount rate (0%, 5%), drug costs (±10%, ±20%) and utilities (±10%). Probabilistic 
sensitivity analysis (PSA) was also performed. Results: At 5 years, glycopyrronium 
bromide accounted a total cost of € 2,225.18 compared to € 2,374.81 accounted for 
tiotropium bromide. Glycopyrronium bromide yielded higher health benefits (4,321 
LYG and 3,388 QALY) than tiotropium bromide (4,315 LYG and 3,377 QALY). In all one-
way sensitivity analyses performed and in 100% of PSA simulations (1,000 iterations), 
glycopyrronium bromide compared to tiotropium bromide remained as a dominant 
strategy. cOnclusiOns: Glycopyrronium bromide therapy in COPD patients is asso-
ciated to less costs and higher health benefits than tiotropium in Spain.
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Objectives: We conducted this pharmacoeconomic study to compare mometa-
sone furoate (M/F), fluticasone propionate (F/P) and budesonide (BUD) in treatment 
of moderate and severe asthma. MethOds: Initially we conducted indirect com-
parison of efficacy and safety of studied therapies through the review of clinical 
data publications. We used cost minimization and cost effectiveness analysis for 
the pharmacoeconomic research. In the study we considered the direct costs of the 
three ICS and additional costs of β 2-adregenic agonist (salbutamol). We made calcula-
tions of costs for the most common treatment regimens in Russia: M/F 400 µg 1 dose 
once a day and F/P 125 µg 2 doses twice a day; M/F 400 µg 1 dose twice a day and F/P 
250 µg 2 doses twice a day; M/F 200 µg, 400 µg 1 dose twice a day and BUD 200 µg 2 
doses twice a day. Results: The review of clinical data demonstrated that M/F has 
similar efficacy to F/P and superior efficacy to BUD. The three ICS have similar safety 
profile. Use of M/F presents 10105 RUR (316 USD) in direct annual per patient costs 
for the treatment of moderate asthma and 20210 RUR (632 USD) for severe asthma. 
Cost minimization analysis showed, that the considered treatment regimens of M/F 
are cost effective compared to F/P 125 µg and 250 µg. M/F will save the health care 
system 28 to 50 USD per patient annually, though these results are price sensitive. 
Cost effectiveness analysis demonstrated that M/F has favorable CER compared to 
BUD: for 1% of FEV1 increase M/F 200 µg is 12 USD, M/F 400 µg is 24 USD and BUD is 
32 USD. These results are insignificantly price sensitive. cOnclusiOns: M/F is the 
most cost effective of the three ICS as demonstrated by the results of cost minimiza-
tion and cost effectiveness analyses.
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Objectives: To evaluate the cost-effectiveness of colistimethate sodium dry 
powder for inhalation (DPI) and tobramycin DPI versus nebulised tobramycin for 
the treatment of Pseudomonas aeruginosalung infection in patients with cystic 
fibrosis. MethOds: We developed a state transition model based on transitions 
between strata of lung function measured in terms of Forced Expiratory Volume in 
1 Second (FEV1) % predicted. Health states representing post-lung transplantation 
and dead are also modelled. The model was informed by systematic reviews of evi-
dence concerning potential relationships between intermediate and final outcomes. 
The model assumes that treatment impacts on FEV1which manifests as changes 
in health-related quality of life. No survival benefit is assumed due to the absence 
of robust evidence. Model parameters were informed by two RCTs and best avail-
able evidence from the literature. Resource costs associated with drug acquisition, 
management of exacerbations and nebuliser maintenance were drawn from refer-
ence sources and expert opinion. Additional analyses of Patient Access Scheme 
(PAS) price discounts offered by the manufacturers of both DPI products were also 
undertaken. Results: Colistimethate sodium DPI is expected to produce fewer 
QALYs than nebulised tobramycin. Based on its list price, nebulised tobramycin is 
expected to dominate colistimethate sodium DPI. When the PAS is incorporated, 
the ICER for colistimethate sodium DPI versus nebulised tobramycin is expected 
to be approximately £288,600 saved per QALY lost. Based on its list price, the ICER 
for tobramycin DPI versus nebulised tobramycin is expected to be approximately 
£124,000 per QALY gained. When the proposed PAS is included, tobramycin DPI is 
expected to dominate nebulised tobramycin. cOnclusiOns: Under their list prices, 
neither DPI product is likely to represent good value for money given current UK 
cost-effectiveness thresholds. The price discounts significantly improve the eco-
nomic attractiveness of both products. The cost-effectiveness of the DPIs against 
other nebulised antibiotics remains unclear.
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simulate the progressive course of COPD and its impact on quality adjusted life years 
(QALYs) in moderate to severe patients. Effectiveness was based on initial FEV1 increase 
included by using patient level improvement in one or more disease severity stages 
(according to GOLD guidelines) and annualized risk for exacerbation as observed in a 
1-year head-to-head randomized controlled trial (GLOW2). Initial FEV1 increase during 
the first year was followed by a constant decline in FEV1 in subsequent cycles. Based on 
list prices, annual drug costs were 3’825 Swedish krona (SEK)/447 EUR for glycopyrronium 
and 5’040 SEK/589EUR for tiotropium. Direct and indirect maintenance and exacerbation 
costs as well as utilities were extracted from published literature. Primary outcomes were 
QALYs and societal costs over 3 years, discounting future costs and benefits at 3%. Both 
one way and probabilistic sensitivity analysis have been performed. Results: Over 3 
years, glycopyrronium was found to be dominant (i.e. less costly and more effective) com-
pared with tiotropium. Treatment with glycopyrronium resulted in a minor QALY gain of 
0.005 compared with tiotropium. Total costs per patient were estimated at 73’752SEK / 
8’630 EUR for glycopyrronium and 79’357 SEK /9’286 EUR for tiotropium, resulting 
in an average cost saving of 5’605SEK /656 EUR per patient after 3 years. Univariate 
sensitivity analyses showed that base-case results were robust and probabilistic sen-
sitivity analyses resulted in 99% of generated samples with glycopyrronium to be 
dominant. cOnclusiOns: From a Swedish societal perspective, glycopyrronium was 
estimated to be cost-effective compared with tiotropium based on the progressive course 
of COPD and risk for exacerbation in moderate to severe patients as observed in the 
head-to-head study GLOW2.
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Objectives: To conduct a cost-effectiveness analysis of carbapenems use (imipenem, 
meropenem, and doripenem) in treatment nosocomial pneumonia. MethOds: Cost-
effectiveness analysis based on decision-tree model was conducted from patient’s 
(out-of-pocket drugs costs) and state (drugs costs and hospitalization expenses) 
perspectives. The input data on therapy duration and drugs’ doses were retrieved 
from randomized controlled trials and clinical standards. The drugs doses were equal 
to: 2.0g /day from imipenem/cilastatin, 3.0g /day for meropenem, and 1.5g/day for 
doripenem. The model considered that in the case of drugs effectiveness the treat-
ment continued till successful outcome, and in a case of non-effective treatment, the 
second line therapy (vancomycin or colomycin depending on type of infection) was 
applied. The data on infections resistance and empirical effectiveness of antibiotics 
were retrieved from the largest microbiologic study conducted in Ukraine. Results: 
The lowest cost- effectiveness ratio correspond to the initial therapy with imipenem/
cilastatin (CER 910$/1158$ vs. 1280$/1648$ for meropenem and 1317$/1712$ for dorip-
enem from state and patient’s perspectives accordingly). cOnclusiOns: Thus, 
empiric therapy with meropenem increases the costs of medical treatment by 29 %, 
with doripenem – by over 35 %. Sensitivity analysis of the results of calculations versus 
changes of level of MRSA-resistant and carbapenem-resistant strains demonstrated 
reliability of the received results.
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Objectives: To determine the cost-effectiveness of palivizumab for the prevention 
of serious lower respiratory tract infection requiring hospitalization caused by RSV 
compared to no prophylaxis in high-risk infants born at 33-35 weeks of gestational 
age (wGA) according to the Dutch RISK model. MethOds: A decision tree model was 
developed using data from published literature, palivizumab clinical trials, the Dutch 
RISK score model, official price/tariff lists and Dutch national population statistic. 
The comparator was no prophylaxis. The primary perspective of the study was that 
of the society in The Netherlands. Time horizon was lifetime. The cost valuation is 
based on the direct health care costs, direct nonmedical costs and indirect costs. 
Costs were assessed in 2012 Euros. The costs and utilities are discounted by 4% and 
1.5%, respectively, from the second year onwards, and no discounting is applied in 
the first year. Results: The base case results show that the use of palivizumab 
leads to an additional cost of € 4,116, whereas the use of palivizumab leads to a 
gain of 0.201 life years and 0.265 QALYs. Although the use of palivizumab increases 
the costs compared with no prophylaxis, palivizumab-treated patients experienced 
more QALYs and a gain in life years. Subsequently, palivizumab results in an ICER of 
€ 15,520 per QALY gained compared to no prophylaxis. The ICER in cost per LYG is € 
20,440. cOnclusiOns: This analysis showed that palivizumab was cost-effective as 
a prophylaxis against RSV infection requiring hospitalisation in high-risk late prema-
ture infants compared to no prophylaxis. Extensive sensitivity analyses and explored 
scenarios underline the robustness of the demonstrated base case cost-effectiveness.
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Objectives: To assess the cost-effectiveness and cost-utility of glycopyrronium 
bromide versus tiotropium bromide in Chronic Obstructive Pulmonary Disease 
(COPD) patients, from the Spanish National Health System perspective. MethOds: 
A Markov model was developed to compare glycopyrronium bromide and tiotro-
pium therapies. Progression of a COPD patient cohort was simulated for a 5-year 
time horizon (3 months-cycle duration). The health states included were defined 
according to the severity of COPD: mild, moderate, severe, very severe and death 
